Barclays’s Revelation Biosciences REVB Stock Holding History
Bought
Maintained
Sold
Other funds holding REVB
SM
Barclays's REVB Position: Q3 2026 in Review
Barclays sold out of Revelation Biosciences (REVB) in Q3 2026, closing a stake of 24 shares — an estimated $173 sold.
Barclays first reported a position in REVB in Q2 2026 and held it in 1 quarter. The position peaked at $173 in Q2 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q3 2026.
- Barclays reported no remaining Revelation Biosciences position as of Q3 2026 after selling out during the quarter.
- Barclays sold 24 Revelation Biosciences shares in Q3 2026, an estimated $173.
- Barclays first reported a position in Revelation Biosciences in Q2 2026 and held it in 1 quarter.
- Barclays's Revelation Biosciences position peaked at $173 in Q2 2026.
- 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.